These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 35585639)
21. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma. Ma W; Mei P World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196 [TBL] [Abstract][Full Text] [Related]
22. The N6-Methylandenosine-Related Gene Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512 [TBL] [Abstract][Full Text] [Related]
23. Identification of prognosis-related gene features in low-grade glioma based on ssGSEA. He Y; Lin Z; Tan S Front Oncol; 2022; 12():1056623. PubMed ID: 36591509 [TBL] [Abstract][Full Text] [Related]
24. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma. Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420 [TBL] [Abstract][Full Text] [Related]
25. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma. Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647 [TBL] [Abstract][Full Text] [Related]
26. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis. Qi C; Lei L; Hu J; Wang G; Liu J; Ou S J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801 [TBL] [Abstract][Full Text] [Related]
27. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma. Wu H; He H; Huang J; Wang C; Dong Y; Lin R; Cheng Z; Qiu Q; Hong L Front Mol Neurosci; 2022; 15():972308. PubMed ID: 36483569 [TBL] [Abstract][Full Text] [Related]
28. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas. Fang Z; Lin L; Tu Z; Zhu X; Li J; Luo P; Huang K; Wu L Cancer Med; 2023 Jan; 12(1):712-732. PubMed ID: 35702880 [TBL] [Abstract][Full Text] [Related]
29. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma. Wen J; Zhao W; Shu X Front Oncol; 2022; 12():1087762. PubMed ID: 36776374 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas. Tan S; Spear R; Zhao J; Sun X; Wang P Front Genet; 2022; 13():905047. PubMed ID: 35832194 [TBL] [Abstract][Full Text] [Related]
31. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
32. Elevated expression of mitochondrial transcription elongation factor (TEFM) predicts poor prognosis in low grade glioma-an analysis of the Cancer Genome Atlas (TCGA) dataset. Li S; Wang W; Zi J; Sun M; Mei W; Yang N; Zhang R; Yu M; Xiong W Transl Cancer Res; 2020 May; 9(5):3610-3622. PubMed ID: 35117724 [TBL] [Abstract][Full Text] [Related]
33. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma. Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y PeerJ; 2024; 12():e16874. PubMed ID: 38406287 [TBL] [Abstract][Full Text] [Related]
34. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas. Li J; Wang J; Ding Y; Zhao J; Wang W BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive Analysis of Inflammatory Response-Related Genes, and Prognosis and Immune Infiltration in Patients With Low-Grade Glioma. Han T; Zuo Z; Qu M; Zhou Y; Li Q; Wang H Front Pharmacol; 2021; 12():748993. PubMed ID: 34712139 [No Abstract] [Full Text] [Related]
36. Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma. Xiao K; Liu Q; Peng G; Su J; Qin CY; Wang XY PeerJ; 2020; 8():e8312. PubMed ID: 31921517 [TBL] [Abstract][Full Text] [Related]
37. Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas Huang X; Zhang F; He D; Ji X; Gao J; Liu W; Wang Y; Liu Q; Xin T Front Oncol; 2021; 11():646060. PubMed ID: 34094933 [TBL] [Abstract][Full Text] [Related]
38. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma. Su X; Li H; Chen S; Qin C Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271 [TBL] [Abstract][Full Text] [Related]
39. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics. Lin WW; Ou GY; Zhao WJ J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473 [TBL] [Abstract][Full Text] [Related]
40. DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma. Lu Y; Chang P; Bian J; Zhu L Cancer Biomark; 2023; 38(3):393-407. PubMed ID: 37955080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]